Valuation: Lophos Holdings Inc.

Market Cap 859K 602K 535K 499K 455K 57.9M 867K 6.04M 2.34M 29.6M 2.26M 2.21M 95M P/E 2023 *
-
P/E 2024 -4.22x
Enterprise Value 2.93M 2.06M 1.83M 1.71M 1.56M 198M 2.96M 20.65M 8M 101M 7.73M 7.56M 325M EV / Sales 2023 *
-
EV / Sales 2024 -
Free-Float
96.11%
Yield 2023 *
-
Yield 2024 -
3 years 0
Extreme 0
0.44
5 years 0
Extreme 0
0.9
10 years 0
Extreme 0
0.9
Manager TitleAgeSince
Chief Executive Officer - 2026-05-05
Director TitleAgeSince
Director/Board Member 41 2021-12-22
Director/Board Member 48 2022-10-31
Director/Board Member - 2026-05-05
Date Insider Type Main position Quantity % Market Cap. Importance
7/13/26 Tax

Director

-500,000 -
7/13/26 Tax -1,426,666 --
7/13/26 Tax -2,000,000 --
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--%-.--%-75.00% 603K
+4.16%+3.04%+49.37%+94.17% 74.41B
-3.11%-3.53%+21.92%+74.60% 59.26B
+0.89%-0.63%+4.28%+34.51% 47.14B
-0.92%-4.56%+26.27%+33.09% 42.91B
+0.43%+0.81%+352.17%+689.61% 44.13B
-1.61%-2.12%+2.33%+97.88% 40.79B
-0.54%+2.93%+9.50%+50.41% 30.77B
-2.68%+5.11%+33.11%+19.50% 29.31B
+0.87%-7.71%-28.84%+328.62% 23.71B
Average -0.28%-0.58%+47.01%+134.74% 39.24B
Weighted average by Cap. -0.00%-0.40%+57.38%+149.87%

Financials

2023 2024
Net sales - -
Net income -988K -693K -616K -575K -524K -66.61M -997K -6.95M -2.69M -34.05M -2.6M -2.54M -109M -1.19M -838K -744K -695K -633K -80.52M -1.21M -8.41M -3.26M -41.16M -3.14M -3.08M -132M
Net Debt 1.92M 1.35M 1.2M 1.12M 1.02M 129M 1.94M 13.5M 5.23M 66.13M 5.05M 4.94M 212M 2.07M 1.46M 1.29M 1.21M 1.1M 140M 2.09M 14.61M 5.66M 71.53M 5.46M 5.35M 230M
Logo Lophos Holdings Inc.
Lophos Holdings Inc. is a Canada-based bioscience company, which is engaged in the cultivation, research and sale of Lophophora williamsii (peyote cactus). The Company is also engaged in the research and development of compounds derived from the peyote cactus. Its cultivated peyote cactus will be used by the Company to conduct pre-clinical research and development in Canada either directly through a Controlled Substance Dealers License (CSDL) at its Napanee facility, or indirectly with one or more third-party partners. Its CSDL licensing includes the development of intellectual property related to the chemical composition of peyote and the custom formulation of Mescaline and related compounds and the research and development of drug delivery systems for Mescaline and other related molecules. It also operates a Health Canada licensed analytical testing and research and development institution, to conduct pre-clinical research and development.
Employees
-
  1. Stock Market
  2. Stocks
  3. MESC Stock